Tuberculosis Diagnosis and Treatment Market
Tuberculosis Diagnosis and Treatment Market Research and Forecast 2017-2022 Update Available - Forecast 2024-2030
Tuberculosis diagnosis and treatment market is expected to grow at a CAGR of 2.3 % during 2017-2022. An infectious disease caused by the bacterium Mycobacterium tuberculosis (MTB) is known as Tuberculosis (TB). Tuberculosis generally affects the lungs, but can also affect other parts of the body. Latent tuberculosis is the type of TB which do not have symptoms. Around 10% of latent infections progress to active disease which, if left untreated, kills about half of those infected. A chronic cough with blood-containing sputum, fever, night sweats, and weight loss are some of the symptoms of active TB. According to WHO Tuberculosis (TB) is one of the top 10 causes of death worldwide. In 2015, 1.8 million died from the disease (including 0.4 million among them were people with HIV), an estimated 1 million children became ill with TB, 10.4 million people fell ill with TB, 170,000 children died of TB (excluding children with HIV) and an estimated 480 000 people developed multidrug-resistant TB (MDR-TB). Around 95% of TB deaths occur in low and middle income countries.
Rising number of TB patients in APAC region is one of the biggest driver which fuels the global market. According to TB facts around 2.2 million people develop TB in India and an estimated 220,000 died from the disease, this costs Indian economy around $340 Million. The rising screening rate in the high burden regions, faster clinical decisions, and affordability of diagnostics, advanced methodologies, and reduction in mortality rate are the major areas of development. Improved preventive and curative diagnosis rates are the end results of these initiatives. This enhances the demand for diagnostic tests and drugs for TB which boosts the Global Tuberculosis diagnosis and treatment market. Though limited diagnostic procedures and lack of knowledge regarding TB diseases acts as a barrier and hinders the growth of Global Tuberculosis diagnosis and treatment market.
Geographical insights
Geographically market is divided into North America, Europe, Asia Pacific and Rest of the World. Asia pacific region is having highest market share owing to high number of people suffering from Tuberculosis, India and China are the major countries in this region. Government’s initiatives towards TB in this region is also very high. Europe is also a growing market as around 323,000 new TB cases are diagnosed in this region this region is one of the high TB priority region. North America is having a lower market share, North America is showing a sluggish yet continuous growth due to higher awareness regarding TB, rapid acceptance of improved but expensive TB tests, well developed healthcare infrastructure, rising healthcare expenditure and so on.
Competitive insights
The Key Players in Tuberculosis Diagnosis market Include Abbott Laboratories, Akonni Biosystems, Inc., Alere, Inc, Becton Dickinson, Bio – Synth Inc., bioMérieux Sa, Cepheid Inc, Eiken Chemical, Epistem Holdings Plc, F. Hoffmann-La Roche Ag, GlaxoSmithKline., Hain Lifesciences, Hologic Corporation, Labatec Pharma, Lupin, Otsuka Novel Products, QIAGEN, Sandoz, Sanofi, Thermo Fisher Scientific, so on partnership, R&D, M&A, product launch are the key strategy adopted in the global tuberculosis diagnosis and treatment market.
Market segmentation
Global Tuberculosis diagnosis and treatment market is segmented on the basis of drugs, diagnosis, end users and regional outlook.
- Global Tuberculosis diagnosis and treatment market Research and Analysis, By Drugs
- Global Tuberculosis diagnosis and treatment market Research and Analysis, By Diagnosis
- Global Tuberculosis diagnosis and treatment market Research and Analysis, By End Users
- Global Tuberculosis diagnosis and treatment market Research and Analysis, By Region
The report covers
- Comprehensive research methodology of global tuberculosis diagnosis market.
- This report also includes detailed and extensive market overview with key analyst insights.
- Exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
- Analysis of regional regulations and other government policies impacting the global tuberculosis diagnosis market.
- Insights about market determinants which are stimulating the global tuberculosis diagnosis market.
- Detailed and extensive market segments with regional distribution of forecasted revenues.
- Extensive profiles and recent developments of market players.
1. REPORT SUMMARY
1.1. RESEARCH METHODS AND TOOLS
1.2. MARKET BREAKDOWN
1.2.1. BY SEGMENTS
1.2.2. BY GEOGRAPHY
1.2.3. BY STAKEHOLDERS
1.2.4. EXCEPTIONS
2. MARKET OVERVIEW AND INSIGHTS
2.1. DEFINITION
2.2. ANALYST INSIGHTS & CURRENT MARKET TRENDS
2.2.1. KEY FINDINGS
2.2.2. RECOMMENDATION
2.2.3. CONCLUSION
2.3. REGULATION
2.3.1.1. UNITED STATES
2.3.1.2. EUROPEAN UNION
2.3.1.3. CHINA
2.3.1.4. INDIA
3. MARKET DETERMINANT
3.1. MOTIVATORS
3.1.1. INCREASING MODERATE COST OF DIAGNOSTICS TESTS
3.1.2. EMERGENCE OF MDR-TB (MULTI DRUG RESISTANCE TUBERCULOSIS) AND XDR-TB (EXTENSIVELY DRUG RESISTANCE TB) STRAINS
3.1.3. RISING PREVALENCE OF TUBERCULOSIS DISEASES IN APAC REGION
3.1.4. INCREASING DEMAND OF TECHNOLOGICAL ADVANCED TESTING PROCEDURES
3.2. RESTRAINT
3.2.1. LIMITED DIAGNOSTIC PROCEDURES
3.2.2. LACK OF AWARENESS ABOUT TUBERCULOSIS
3.3. OPPORTUNITY
3.3.1. INCREASING SPENDING ON R&D
3.3.2. GOVERNMENT INITIATIVES TOWARDS TUBERCULOSIS SUCH AS REVISED NATIONAL TB CONTROL PROGRAM (RNTCP)
4. MARKET SEGMENTATION
4.1. BY DRUGS
4.1.1. FIRST LINE DRUGS
4.1.1.1. PYRAZINAMIDE (Z/PZA)
4.1.1.2. ETHAMBUTOL (E/EMB)
4.1.1.3. RIFABUTIN (RFB)
4.1.1.4. ISONIAZID
4.1.1.5. RIFAMPICIN
4.1.1.6. RIFAPENTINE
4.1.1.7. STREPTOMYCIN
4.1.2. SECOND LINE DRUGS
4.1.2.1. INJECTABLE AGENTS
4.1.2.1.1. KAMAMYCIN(KM)
4.1.2.1.2. AMIKACIN(AMK)
4.1.2.1.3. CAPREOMYCIN(CM)
4.1.2.2. FLUOQUINOLONES
4.1.2.2.1. LEVOFLOXACIN(LFX)
4.1.2.2.2. MOXIFLOXACIN(MFX)
4.1.2.2.3. OFLAXACIN (OFX)
4.1.2.3. ORAL BACTERIOSTATIC SECOND LINE AGENT
4.1.2.3.1. ETHIONAMIDE (ETO)
4.1.2.3.2. PROTHIONAMIDE(PTO)
4.1.2.3.3. CYCLOSERINE(DCS)
4.1.2.3.4. TERIZIDONE(TRD)
4.1.2.3.5. PARA-AMINOSALICYCLIC ACID(PAS)
4.1.2.4. AGENTS WITH AN UNCLEAR ROLE IN TREATMENT OF DRUG RESISTANT TB
4.1.2.4.1. CLOFAZIMINE(CFZ)
4.1.2.4.2. LINEZOLID(LZD)
4.1.2.4.3. AMOXICILLIN-CLAVULANIC ACID (AMX/CIV)
4.1.2.4.4. THIACETAZONE
4.1.2.4.5. HIGH DOSE ISONIAZID
4.1.2.4.6. CLARITHROMYCIN(CLR)
4.1.2.4.7. IMIPENEM (IPM)
4.2. BY DIAGNOSIS
4.2.1. LABORATORY TESTING
4.2.1.1. SMEAR MICROSCOPY
4.2.1.2. CULTURE BASED TEST
4.2.2. NUCLEIC ACID TESTS
4.2.3. MANTOUX TEST
4.2.4. RADIOGRAPHY
4.2.5. DRUG SUSCEPTIBILITY TEST
4.2.6. OTHER TESTS
4.3. BY END USERS
4.3.1. HOSPITALS
4.3.2. GOVERNMENT ORGANIZATIONS
4.3.3. INDIVIDUAL
4.3.4. OTHERS
5. COMPETITIVE LANDSCAPE
5.1. KEY STRATEGIES
5.2. KEY COMPANY ANALYSIS
6. REGIONAL ANALYSIS
6.1. NORTH AMERICA
6.1.1. UNITED STATES
6.1.2. CANADA
6.2. EUROPE
6.2.1. UK
6.2.2. GERMANY
6.2.3. SPAIN
6.2.4. FRANCE
6.2.5. ITALY
6.2.6. ROE
6.3. ASIA PACIFIC
6.3.1. INDIA
6.3.2. CHINA
6.3.3. JAPAN
6.3.4. ROAPAC
6.4. REST OF THE WORLD
7. COMPANY PROFILES (COMPANY OVERVIEW, PRODUCT PORTFOLIO, RECENT DEVELOPMENTS, REVENUE ANALYSIS)
7.1. ABBOTT LABORATORIES
7.2. AKONNI BIOSYSTEMS, INC.
7.3. ALERE, INC.
7.4. BECTON DICKINSON AND CO.
7.5. BIO – SYNTH INC.
7.6. BIOMÉRIEUX SA
7.7. CEPHEID INC
7.8. EIKEN CHEMICAL CO. LTD.
7.9. EPISTEM HOLDINGS PLC
7.10. F. HOFFMANN-LA ROCHE AG
7.11. HAIN LIFESCIENCES GMBH
7.12. HOLOGIC CORPORATION
7.13. GLAXOSMITHKLINE
7.14. LABATEC PHARMA SA
7.15. LUPIN
7.16. OTSUKA NOVEL PRODUCTS GMBH
7.17. QIAGEN
7.18. SANDOZ
7.19. SANOFI
7.20. THERMO FISHER SCIENTIFIC, INC
TABLE # 1 GLOBAL TUBERCULOSIS DIAGNOSIS AND TREATMENT MARKET RESEARCH AND ANALYSIS, BY TECHNOLOGY 2016-2022 ($ MILLION)
TABLE # 2 GLOBAL TUBERCULOSIS DIAGNOSIS AND TREATMENT, BY DRUGS MARKET RESEARCH AND ANALYSIS 2016-2022 ($ MILLION)
TABLE # 3 GLOBAL FIRST LINE DRUGS MARKET RESEARCH AND ANALYSIS 2016-2022 ($ MILLION)
TABLE # 4 GLOBAL PYRAZINAMIDE (Z/PZA) MARKET RESEARCH AND ANALYSIS 2016-2022 ($ MILLION)
TABLE # 5 GLOBAL ETHAMBUTOL (E/EMB) MARKET RESEARCH AND ANALYSIS 2016-2022 ($ MILLION)
TABLE # 6 GLOBAL RIFABUTIN (RFB) MARKET RESEARCH AND ANALYSIS 2016-2022 ($ MILLION)
TABLE # 7 GLOBAL SECOND LINE DRUGS MARKET RESEARCH AND ANALYSIS 2016-2022 ($ MILLION)
TABLE # 8 GLOBAL CAPREOMYCIN MARKET RESEARCH AND ANALYSIS 2016-2022 ($ MILLION)
TABLE # 9 GLOBAL LEVOFLOXACIN MARKET RESEARCH AND ANALYSIS 2016-2022 ($ MILLION)
TABLE # 10 GLOBAL CLOFAZIMINE MARKET RESEARCH AND ANALYSIS 2016-2022 ($ MILLION)
TABLE # 11 GLOBAL AMIKACIN MARKET RESEARCH AND ANALYSIS 2016-2022 ($ MILLION)
TABLE # 12 GLOBAL PARA-AMINOSALICYLIC ACID (PAS) MARKET RESEARCH AND ANALYSIS 2016-2022 ($ MILLION)
TABLE # 13 GLOBAL TUBERCULOSIS DIAGNOSIS AND TREATMENT, BY DIAGNOSIS MARKET RESEARCH AND ANALYSIS 2016-2022 ($ MILLION)
TABLE # 14 GLOBAL SMEAR MICROSCOPY MARKET RESEARCH AND ANALYSIS 2016-2022 ($ MILLION)
TABLE # 15 GLOBAL CULTURE BASED TESTS MARKET RESEARCH AND ANALYSIS 2016-2022 ($ MILLION)
TABLE # 16 GLOBAL NUCLEIC ACID TESTS MARKET RESEARCH AND ANALYSIS 2016-2022 ($ MILLION)
TABLE # 17 GLOBAL MANTOUX TEST MARKET RESEARCH AND ANALYSIS 2016-2022 ($ MILLION)
TABLE # 18 GLOBAL RADIOGRAPHY MARKET RESEARCH AND ANALYSIS 2016-2022 ($ MILLION)
TABLE # 19 GLOBAL DRUG SUSCEPTIBILITY TEST MARKET RESEARCH AND ANALYSIS 2016-2022 ($ MILLION)
TABLE # 20 GLOBAL OTHER TESTS MARKET RESEARCH AND ANALYSIS 2016-2022 ($ MILLION)
TABLE # 21 GLOBAL TUBERCULOSIS DIAGNOSIS AND TREATMENT, BY END USERS MARKET RESEARCH AND ANALYSIS 2016-2022 ($ MILLION)
TABLE # 22 GLOBAL HOSPITALS MARKET RESEARCH AND ANALYSIS 2016-2022 ($MILLION)
TABLE # 23 GLOBAL GOVERNMENT ORGANIZATIONS MARKET RESEARCH AND ANALYSIS 2016-2022 ($ MILLION)
TABLE # 24 GLOBAL INDIVIDUAL MARKET RESEARCH AND ANALYSIS 2016-2022 ($ MILLION)
TABLE # 25 GLOBAL OTHERS MARKET RESEARCH AND ANALYSIS 2016-2022 ($ MILLION)
FIGURE # 1 NORTH AMERICAN MARKET RESEARCH AND ANALYSIS, 2016-2022 ($ MILLION)
FIGURE # 2 UNITED STATES MARKET RESEARCH AND ANALYSIS, 2016-2022 ($ MILLION)
FIGURE # 3 CANADA MARKET RESEARCH AND ANALYSIS, 2016-2022 ($ MILLION)
FIGURE # 4 EUROPEAN MARKET RESEARCH AND ANALYSIS, 2016-2022 ($ MILLION)
FIGURE # 5 UK MARKET RESEARCH AND ANALYSIS, 2016-2022 ($ MILLION)
FIGURE # 6 GERMANY MARKET RESEARCH AND ANALYSIS, 2016-2022 ($ MILLION)
FIGURE # 7 SPAIN MARKET RESEARCH AND ANALYSIS, 2016-2022 ($ MILLION)
FIGURE # 8 FRANCE MARKET RESEARCH AND ANALYSIS, 2016-2022 ($ MILLION)
FIGURE # 9 ITALY MARKET RESEARCH AND ANALYSIS, 2016-2022 ($ MILLION)
FIGURE # 10 ROE MARKET RESEARCH AND ANALYSIS, 2016-2022 ($ MILLION)
FIGURE # 11 ASIA PACIFIC MARKET RESEARCH AND ANALYSIS, 2016-2022 ($ MILLION)
FIGURE # 12 INDIA MARKET RESEARCH AND ANALYSIS, 2016-2022 ($ MILLION)
FIGURE # 13 CHINA MARKET RESEARCH AND ANALYSIS, 2016-2022 ($ MILLION)
FIGURE # 14 JAPAN MARKET RESEARCH AND ANALYSIS, 2016-2022 ($ MILLION)
FIGURE # 15 ROPAC MARKET RESEARCH AND ANALYSIS, 2016-2022 ($ MILLION)
FIGURE # 16 REST OF THE WORLD MARKET RESEARCH AND ANALYSIS, 2016-2022 ($ MILLION)
